Kiniksa Pharmaceuticals announced positive data from the phase 3 RHAPSODY trial evaluating rilonacept for the treatment of recurrent pericarditis.
Inhibition of sclerostin with romosozumab may increase cardiovascular risk, according to research published in the June 24 issue of Science Translational Medicine.
Low thyroid function is associated with nonalcoholic fatty liver disease and predicted all-cause and cardiovascular mortality in this population.
The American Heart Association outlined several considerations for the management of pregnant women with CVD or CVD-related conditions.
Cardioprotective therapies, especially statins and antiplatelets, are underutilized in patients with a history of cancer (CaHx).
CMR criteria along with family history can determine those patients in whom a (likely) pathogenic variant for noncompaction cardiomyopathy can be identified.
A team of investigators reviewed data from institutions within the VA healthcare system to assess the ability of 2 algorithms to identify patients with intravenous drug use-associated infective endocarditis.
Higher blood pressure (BP) during exercise and impaired BP recovery after exercise in midlife may be markers of subclinical and clinical cardiovascular disease and mortality in later life.
Outpatient azithromycin use is associated with an increased risk for cardiovascular and noncardiovascular mortality.
Baseline diastolic blood pressure does not affect the cardiovascular benefits of intensive lowering of systolic blood pressure in patients with type 2 diabetes.